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Abstract
Background The aim of this study was to examine the difference in outcome between hand-assisted retroperitoneoscopic 
and laparoscopic living donor nephrectomy in obese donors, and the impact of donor body mass index on outcome.
Methods Out of 1108 living donors who underwent hand-assisted retroperitoneoscopic or laparoscopic donor nephrectomy 
between 2010 and 2018, 205 were identified having body mass index ≥ 30. These donors were included in this retrospective 
study, analyzing postoperative outcomes and remnant renal function.
Results Out of 205 donors, 137 (66.8%) underwent hand-assisted retroperitoneoscopic donor nephrectomy and 68 donors 
(33.2%) underwent laparoscopic donor nephrectomy. Postoperative outcome did not show any significant differences between 
the hand-assisted retroperitoneoscopic donor nephrectomy group and the laparoscopic donor nephrectomy group in terms 
of major complications (2.2% vs. 1.5%, P = 0.72), postoperative pain scale (4 vs. 4, P = 0.67), and the length of stay (3 days 
vs. 3 days, P = 0.075). The results of kidney function in donors after nephrectomy demonstrated no significant differences 
between the groups. Additional analysis of 29 donors with body mass index ≥ 35 (14.1%) as compared with 176 donors 
with body mass index 30–35 (85.9%) revealed no significant differences between groups in postoperative outcomes as well 
as kidney function after donation.
Conclusion Our results show that laparoscopic living donor nephrectomy for obese donors is safe and feasible with good 
postoperative outcomes. There were no significant differences regarding postoperative outcome between hand-assisted 
retroperitoneoscopic and laparoscopic donor nephrectomy. Furthermore, the outcome in donors with body mass index ≥ 35 
was comparable to donors with body mass index 30–35.
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Kidney transplantation is the most effective option in treat-
ing end-stage renal disease. Due to a persistent shortage of 
deceased donor organs, living donor kidney transplantation 
is considered as an excellent alternative to expand the kid-
ney donor pool. Careful selection criteria for living donors 
are warranted because donor nephrectomy can cause com-
plications, including short-term and long-term, in healthy 
individuals. The body mass index (BMI) is one of the simple 
parameters used for donor selection. In most transplant cent-
ers, a BMI ≥ 35 is considered as a relative contraindication 
to be a donor [1–4]; however clear cut-off values of BMI are 
still under debate and further investigations are needed to 
clarify the significance of donor BMI on outcome not only 
in donors but also in recipients.
A previous meta-analysis reported that donors with 
BMI ≥ 30 had significantly longer operative time, higher 
conversion risk, and increased serum creatinine levels after 
laparoscopic donor nephrectomy, even though other short-
term outcome such as postoperative complications, length of 
stay (LOS) did not show significantly differences [5]. In con-
trast, the Organ Procurement and Transplantation Network 
registry data have shown good outcomes for obese donors 
(BMI ≥ 30) and their recipients [6]. However, the question 
whether laparoscopic living donor nephrectomy is safe and 
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feasible in obese donors, and whether there are any differ-
ences regarding short-term outcome between hand-assisted 
retroperitoneoscopic (HARP) and pure laparoscopic (LDN) 
living donor nephrectomy in obese donors, is unknown.
The aim of this study was to compare the outcome 
between HARP and LDN in donors with BMI ≥ 30. Further-
more, we evaluated the impact of donor BMI on outcome 
after living donor nephrectomy.
Materials and methods
We retrospectively reviewed the kidney transplant database 
including 1108 consecutive living donors who underwent a 
donor nephrectomy at the Erasmus MC, University Medical 
Centre Rotterdam, The Netherlands, between January 2010 
and December 2018. Among 1108 living donors, 205 donors 
with BMI ≥ 30 were extracted. This study was approved by 
the Ethics Committee of the Erasmus MC, and was con-
ducted in accordance with the tenets of the Declaration of 
Helsinki.
Clinical data
For all enrolled donors, the following demographic and clin-
ical data were collected: gender, age, height, weight, BMI, 
American Society of Anesthesiologists (ASA) physical sta-
tus, history of hypertension, and relationship between donors 
and recipients. BMI was categorized into two groups: BMI 
30–35 and BMI ≥ 35. Regarding the operative outcome, the 
type of donor nephrectomy (HARP vs. LDN), the side of the 
donor nephrectomy (right vs. left kidney), conversion rate to 
open donor nephrectomy, operative time and blood loss were 
evaluated. Data on major postoperative complications, mor-
tality, maximum pain scale after surgery until discharge, and 
the postoperative LOS were recorded as postoperative out-
comes. The postoperative major complications were defined 
as Clavien-Dindo classification grade 3 or higher [7]. Pain 
scale was evaluated by the Numeric Pain Rating Scale in 
which a patient selected a whole number (0–10 integers): 0, 
no pain; 1–3, mild pain; 4–6, moderate pain; 7–10, severe 
pain [8]. Serum creatinine level (mg/dL) and the estimated 
glomerular filtration rate (eGFR, mL/min/1.73 m2) before 
donor nephrectomy and after 1 month, 3 month, and 1 year 
were analyzed.
Surgical technique
The details of surgical techniques employed were previ-
ously described [9, 10]. The selection for LDN or HARP 
was based on the surgeon preference. Both procedures 
were performed with the donor placed in right- or left-
decubitus position. In LDN, the first trocar was introduced 
under direct vision, the abdomen was insufflated with car-
bon dioxide to 14 cmH2O pressure and a 30° video endo-
scope and 3 or 4 additional trocars were introduced. The 
colon was mobilized and displaced medially, and opening 
of the renal capsule and division of the perirenal fat was 
facilitated using an ultrasonic device (Harmonic, Ethicon, 
Cincinnati, USA). After identification and dissection of 
the ureter, the renal artery, and the renal vein, a Pfan-
nenstiel incision was made. An endobag (Endocatch, US 
surgical, Norwalk, USA) was introduced into the abdo-
men. The ureter was clipped distally and divided. The 
renal artery and vein were divided using an endoscopic 
stapler (EndoGia, US Surgical, Norwalk, USA). The kid-
ney was placed in the endobag and extracted through the 
Pfannenstiel incision.
In HARP, we started with a 7–10 cm Pfannenstiel inci-
sion. After blunt dissection to create a retroperitoneal space, 
a Gelport (Applied Medical, Rancho Santa Margarita, Cali-
fornia, USA) was inserted. Blunt introduction of the first 
trocar between the iliac crest and the handport was guided 
by the operating surgeon’s hand inside the abdomen through 
the Gelport. Carbon dioxide was insufflated retroperitoneally 
to 14 cm  H2O pressure. Two other 10–12 mm trocars, just 
outside the midline inferior to the costal margin and in the 
flank respectively, were inserted to create a triangular shape. 
For dissection, the aforementioned Harmonic device was 
used. Dissection of the kidney and dissection and cutting 
of the renal vessels and ureter were similar to transperito-
neal donor nephrectomy but with hand assistance and from 
a slightly different angle. The kidney was extracted manually 
and flushed on the back table.
Statistical analysis
First, donor characteristics and outcome were compared 
between HARP and LDN groups. Second, the outcome 
between donors with BMI 30–35 and with BMI ≥ 35 was 
analyzed. Finally, the outcome of donors with BMI ≥ 30 was 
compared to those with BMI < 30 using a propensity score 
matching (PSM). The PSM was conducted using a logistic 
regression model including preoperative variables with P 
value < 0.20 (6 variables in total), as previously reported 
[11]. Propensity scores were matched with one-to-one ratio 
using a caliper width 0.20 of the standard deviation. Data 
were presented as medians and the interquartile range (IQR) 
for continuous variables. Categorical data were presented 
as proportions. Differences between groups were assessed 
using the Mann–Whitney U-test for continuous variables, 
and Fisher’s exact test or Chi square test for categorical vari-
ables. JMP version 11 software (SAS Institute, Cary, NC) 
was used for all statistical analyses. A P value < 0.05 was 
considered statistically significant.
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Results
Study cohort
The annual volumes of living donor nephrectomy in 
donors with BMI ≥ 30 between 2010 and 2018 at the 
Erasmus MC are shown in Fig. 1. The demographic char-
acteristics of the 205 donors are shown in Table 1. Hyper-
tension was found in 43 donors (21.0%). Regarding the 
relationship between donors and recipients, 101 (49.2%) 
were related, 67 (32.7%) were unrelated, 26 (12.7%) were 
cross over, and 11 (5.4%) were non-directed. Regarding 
operative outcome, 153 (74.6%) were left and 52 (25.4%) 
were right donor nephrectomy. Conversion rate to open 
donor nephrectomy was 0%. The median operative time 
was 161 min (IQR, 128–193 min) and the median blood 
loss was 168 mL (IQR, 50–330 mL). The incidence of 
postoperative major complications was 2.0%. There was no 
reoperation or mortality after surgery. The maximum pain 
scale after surgery was 4 (IQR, 2–5). The median LOS was 
3 days (IQR, 3–4 days).
Fig. 1  Annual volume of HARP and LDN in obese donors between 
2010 and 2018 at Erasmus MC. HARP, hand-assisted retroperitoneo-
scopic living donor nephrectomy; LDN, laparoscopic living donor 
nephrectomy
Table 1  Characteristics between 
HARP and LDN in donors with 
BMI ≥ 30
Data were presented as numbers (percentages) or median (interquartile range)
HARP hand-assisted retroperitoneoscopic living donor nephrectomy, LDN laparoscopic living donor 
nephrectomy, BMI body mass index, ASA American Society of Anesthesiologists physical status, CDc Cla-
vien–Dindo classification, LOS length of stay
Total HARP LDN P value
No of donors 205 137 68
Gender (M/F) 79/126 58/79 21/47 0.11
Age (years) 50.5 (41–60.3) 51.8 (42.5–60.7) 48.3 (37.5–58.6) 0.12
Height (cm) 169 (163.5–177) 170 (165–178) 167.5 (162.3–174.8) 0.03
Weight (kg) 93 (85–102.5) 95 (87–104.3) 90 (83–97.8) 0.002
BMI (kg/m2) 32.4 (31.1–33.9) 32.6 (31.2–34.1) 31.8 (30.8–33.4) 0.034
ASA (1/2/3) 96/108/1 63/73/1 33/35/0 0.64
Hypertension 43 (21.0) 31 12 0.41
Relationship
 Related 101 (49.2) 66 35 0.047
 Unrelated 67 (32.7) 50 17
 Cross over 26 (12.7) 12 14
 Non-directed 11 (5.4) 9 2
Operative
 Right/left kidney 52/153 29/108 23/45 0.053
 Conversion to open 0 (0) 0 (0) 0 (0) –
 Time (min) 161 (128–193) 165 (133–198) 155 (116–190) 0.10
 Blood loss (mL) 168 (50–330) 200 (100–400) 67.5 (20–200) < 0.001
Postoperative
 Major complications (CDc ≥ 3) 4 (2.0) 3 (2.2) 1 (1.5) 0.72
 Reoperation 0 (0) 0 (0) 0 (0) –
 Mortality 0 (0) 0 (0) 0 (0) –
 Pain scale (max) 4 (2–5) 4 (2–5) 4 (2.3–5) 0.67
 LOS (days) 3 (3–4) 3 (3–4) 3 (2–3) 0.075
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Comparison between hand‑assisted 
retroperitoneoscopic versus pure laparoscopic 
donor nephrectomy in donors with BMI ≥ 30
Perioperative outcomes are also summarized in Table 1. 
Out of 205 donors, 137 (66.8%) underwent HARP and 68 
(33.2%) underwent LDN. BMI was significantly higher in 
the HARP group than that in the LDN group (32.6 kg/m2 vs. 
31.8 kg/m2, P = 0.034). Left donor nephrectomy was more 
common in the HARP group compared to the LDN group 
(78.8% vs. 66.2%, P = 0.053). The operative time was not 
significantly different (165 min vs. 155 min, P = 0.10); how-
ever, blood loss was significantly higher in the HARP group 
(200 mL vs. 67.5 mL, P < 0.001). Postoperative outcome 
did not show any significant differences between the HARP 
group and the LDN group in terms of major complications 
(2.2% vs. 1.5%, P = 0.72), pain scale (4 vs. 4, P = 0.67), and 
the LOS (3 days vs. 3 days, P = 0.075).
The results of kidney function after nephrectomy are 
shown in Table 2. Serum creatinine level and the eGFR 
before nephrectomy and after 1 month, 3 month, and 1 year 
demonstrated no significant differences between the groups.
Comparison between donors with BMI 30–35 
versus with BMI ≥ 35
The results of comparison between donors with BMI 30–35 
and with BMI ≥ 35 are shown in Table 3. 176 donors (85.9%) 
were identified having BMI 30–35 and 29 (14.2%) having 
BMI ≥ 35. No significant differences between the groups 
were found in terms of demographic characteristics and 
operative factors. Regarding postoperative outcome, there 
were no significant differences between the two groups in the 
incidence of major complications (1.7% vs. 3.5%, P = 0.56) 
and the LOS (3 days vs. 3 days, P = 0.68). The results of 
kidney function showed no significant differences between 
the groups. At 1 year after nephrectomy, rise in creatinine 
and decline in eGFR were similar between donor BMI 
categories.
Comparison between donors with BMI < 30 
versus with BMI ≥ 30 using the propensity score 
matching
Donor characteristics before and after PSM are demon-
strated in Table 4. Donors with BMI ≥ 30 were younger and 
had higher ASA and more hypertension than donors with 
BMI < 30. In addition, LDN was much common in donors 
with BMI < 30 than those with BMI ≥ 30 (77.9% vs 33.2%, 
P < 0.001). After PSM, both groups were well adjusted for 
matched variables. The receiver- operating characteristic 
curve area under curve was 0.778. Postoperative outcomes 
and kidney function were not significantly different between 
the groups.
Discussion
The present study shows the clinical outcome after laparo-
scopic living donor nephrectomy in a single-center series 
of 205 donors with BMI ≥ 30 at the Erasmus MC. The 
results suggest that laparoscopic living donor nephrectomy 
for donors with BMI ≥ 30 is safe and feasible with good 
postoperative outcomes including no conversion rate, low 
major complication risk, and short LOS. In addition, we 
found no significant differences between HARP and LDN 
in terms of operative outcome, postoperative outcome 
and postoperative kidney function except for blood loss. 
Table 2  Perioperative kidney 
function between HARP and 
LDN in donors with BMI ≥ 30
Data were presented as median (interquartile range)
HARP hand-assisted retroperitoneoscopic living donor nephrectomy, LDN laparoscopic living donor 
nephrectomy, eGFR estimated glomerular filtration rate
Total (n = 205) HARP (n = 137) LDN (n = 68) P value
Creatinine (mg/dL)
 Pre 73 (65.5–83) 73 (65.5–82.5) 73 (64.5–83) 0.84
 1 month 111 (96–128) 112 (96–129) 108 (96.3–124) 0.61
 3 month 109 (95–123) 111 (96–123.5) 105 (92–123.8) 0.56
 1 year 106 (93–123) 106 (94–123) 105 (93–123) 0.62
 Delta (1 year—pre) 34 (27–42.8) 34 (27–45) 33 (25.5–41) 0.24
eGFR (mL/min/1.73 m2)
 Pre 85 (73.5–90) 84 (73–90) 86 (74–90) 0.24
 1 month 52 (45–59) 51 (44–58) 53 (46–60) 0.39
 3 month 53 (46–61) 52 (46–60) 55.5 (46–63) 0.35
 1 year 54 (48–61) 54 (48–61) 55 (48.5–60) 0.79
 Delta (1 year—pre) − 27 (− 33 to − 23) − 27 (− 33 to − 23) − 27 (− 33 to − 22) 0.90
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Furthermore, no impact of donor BMI on perioperative 
outcome and kidney function was found between donors 
with BMI 30–35 and with BMI ≥ 35 as well as between 
donors with BMI < 30 and with BMI ≥ 30.
Regarding postoperative outcomes in donors with 
BMI ≥ 30, all procedures were done laparoscopically with 
no conversion to open donor nephrectomy and no reop-
eration after surgery. The outcome was better when com-
pared with previous studies that reported the conversion 
rate to open procedure with 1.6–2.7% and reoperation with 
0.2–0.4% in donors with BMI ≥ 30 [5, 6, 12]. Our institute 
is one of the largest centers in living kidney donation and 
transplantation in Western Europe, therefore the beneficial 
effect of hospital volumes might result in better outcome. 
Actually several studies have reported that outcomes at 
higher volume centers are better following laparoscopic 
donor nephrectomy and kidney transplantation [13–15].
No previous studies have investigated the outcome 
between HARP and LDN in donors with BMI ≥ 30 so far. 
Our results demonstrated that operative and postoperative 
outcomes as well as postoperative kidney function did not 
show any differences except for intraoperative blood loss. 
Therefore we believe LDN would be possible even in donors 
with BMI ≥ 30. Actually 57% of procedures were done by 
LDN in 2017 and 2018. In contrast, HARP was often con-
ducted at the left kidney (78.8%), although not statistically 
significant. HARP is considered more challenging at the 
right side, due to interference of the liver. Furthermore, the 
use of HARP or LDN did not have any effect on postopera-
tive pain.
With respect to comparison between donors with BMI 
30–35 and with BMI ≥ 35, donors with BMI ≥ 35 had com-
parable operative and postoperative outcomes to donors 
with BMI 30–35. Furthermore, donors with BMI ≥ 30 had 
Table 3  Characteristics between 
donors with BMI 30–35 versus 
with BMI ≥ 35
Data were presented as numbers (percentages) or median (interquartile range)
BMI body mass index, ASA American Society of Anesthesiologists physical status, HARP hand-assisted 
retroperitoneoscopic living donor nephrectomy, LDN laparoscopic living donor nephrectomy, CDc Cla-
vien–Dindo classification, LOS length of stay, eGFR estimated glomerular filtration rate
BMI 30–35 BMI ≥ 35 P value
No of donors 176 29
Gender (M/F) 71/105 8/21 0.18
Age (years) 50.5 (41.1–61.3) 49.9 (42.3–55.6) 0.66
ASA (1/2/3) 85/91/0 11/17/1 0.09
Hypertension 34 9 0.17
Operative
 HARP/LDN 116/60 21/8 0.48
 Right/left kidney 46/130 6/23 0.52
 Conversion to open 0 (0) 0 (0) –
 Time (min) 161 (127–192) 162 (134–209) 0.62
 Blood loss (mL) 165 (50–300) 200 (18.5–392) 0.95
Postoperative
 Major complications (CDc ≥ 3) 3 (1.7) 1 (3.5) 0.56
 LOS (days) 3 (3–4) 3 (2.5–4) 0.68
Kidney function
Creatinine (mg/dL)
 Pre 73.5 (66–82.8) 68 (61–83.5) 0.20
 1 month 111 (97–128) 104 (88.5–123.3) 0.16
 3 month 110 (96–124) 102 (92–122) 0.16
 1 year 107 (95–124) 101 (91.5–122) 0.41
 Delta (1 year—pre) 34 (27–43) 35 (24–43) 0.60
eGFR (mL/min/1.73 m2)
 Pre 85 (73–90) 86 (76–90) 0.82
 1 month 51 (44.3–58.8) 52.5 (48.3–63.3) 0.32
 3 month 53 (46–60) 56 (47–61) 0.51
 1 year 54 (48–61) 54 (47.5–62) 0.72
 Delta (1 year—pre) − 27 (− 33 to − 23) − 27 (− 31 to − 20.5) 0.58
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similar postoperative outcomes compared to donors with 
BMI < 30. These results suggest that laparoscopic living 
donor nephrectomy for donors with BMI ≥ 30 is safe and fea-
sible when looking at short-term outcome, without compro-
mising outcomes. In addition, kidney function 1 year after 
donation did not differ significantly across the groups. This 
result supports a precious report that showed donor BMI was 
not associated with decline in eGFR and percent change in 
creatinine level at 6 month after kidney donation [6].
Regarding eligibility criteria for living kidney donor, 
the CARI guidelines considered obesity (BMI > 30) as 
a relative contraindication to donation [4]. The Brit-
ish guidelines recommended that individuals with BMI 
30–35 should undergo careful preoperative evaluation, 
and individuals with BMI > 35 should be discouraged 
from donating because of limited data [16]. The consensus 
statement of the Amsterdam Forum on the Care of the 
Live Kidney Donor also recommended that individuals 
with BMI > 35 should be discouraged from donating, 
especially when other comorbidities are present [17]. In 
contrast, The European Association of Urology and the 
Canadian guidelines have not provided any recommenda-
tions for donors with BMI > 30 [18–20]. Accordingly, the 
question concerning applicable cut-off values of BMI for 
obese donors remains under debate. A recent systematic 
review has concluded that the selection of potential kidney 
donors should not be based on BMI alone, and high BMI 
should not be considered as an absolute contraindication 
for living kidney donation. The transplant community 
should carefully screen each obese individual and make a 
selection for donation by an obese potential donor with a 
careful individualized process [21].
Table 4  Characteristics of donors with BMI < 30 and BMI ≥ 30: overall and propensity score matching cohort
Data were presented as means (standard deviation) or numbers (percentages)
BMI body mass index, PSM propensity score matching, ASA American Society of Anesthesiologists, HARP hand-assisted retroperitoneoscopic 
living donor nephrectomy, LDN laparoscopic living donor nephrectomy, CDc Clavien–Dindo classification, LOS length of stay, eGFR estimated 
glomerular filtration rate
Variables Before PSM (n = 1108) After PSM (n = 402)
BMI < 30 BMI ≥ 30 P value BMI < 30 BMI ≥ 30 P value
No of donors 903 205 201 201
Gender (M/F) 392/511 79/126 0.20 76/125 77/124 0.92
Age (years) 55.0 (42.3–62.8) 50.5 (41.3–60.3) 0.03 52.8 (41.7–60.9) 50.7 (41.6–60.4) 0.58
ASA (1/2/3) 552/347/4 96/108/1 <0.001 91/109/1 96/104/1 0.88
Hypertension 115 (12.7) 43 (21.0) 0.004 37 (18.4) 40 (19.9) 0.70
Operative
 HARP/LDN 200/703 137/68 <0.001 134/67 133/68 0.92
 Right/left kidney 288/615 51/154 0.046 53/148 50/151 0.73
 Time (min) 152 (126–190) 161 (128–193) 0.17 152 (128–187) 161 (128–194) 0.22
 Blood loss (mL) 50 (10–150) 168 (50–330) <0.001 100 (50–200) 168 (50–330) 0.006
Postoperative
 Major complications 
(CDc ≥ 3)
7 (0.8) 3 (1.5) 0.38 1 (0.5) 3 (1.5) 0.30
 LOS (days) 3 (2–4) 3 (3–4) 0.81 3 (3–4) 3 (3–4) 0.43
Kidney function
Creatinine (mg/dL)
 Pre 75 (65–84) 73 (65.5–83) 0.21 74 (65.3–82) 73 (66–83) 0.98
 1 month 111 (97–127) 111 (96–128) 0.60 111 (98–126) 111 (97–128) 0.80
 3 month 110 (97–125) 109 (95–123) 0.51 111 (98–120) 109 (96–124) 0.89
 1 year 108 (95–124) 106 (93–123) 0.94 108 (95–120) 107 (93–123) 0.63
Delta (1 year—pre) 33 (27–43) 34 (27–42.8) 0.39 34 (27–43) 34 (27–42.8) 0.66
eGFR (mL/min/1.73 m2)
 Pre 84 (73–90) 85 (73.5–90) 0.45 83 (72–90) 85 (73.5–90) 0.48
 1 month 52 (45–59) 52 (45–59) 0.87 51 (45–58) 52 (45–58) 0.45
 3 month 53 (46–61) 53 (46–61) 0.72 51 (46–59) 53 (46–61) 0.37
 1 year 54 (46–62) 54 (48–61) 0.75 53 (46–62) 54 (48–61) 0.76
Delta (1 year—pre) − 26 (− 32 to − 20) − 27 (− 33 to − 23) 0.21 − 25 (− 33 to − 19) − 27 (− 33 to − 23) 0.17
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Another important issue would be the ethical aspect 
for long-term outcome after living donor nephrectomy in 
obese donors. Obese donors (BMI ≥ 30) have been reported 
to have an increased risk of diabetes mellitus, hypertension, 
and end-stage renal disease compared to non-obese donors 
(BMI < 30) during long-term follow-up after donation, 
although the absolute risk for these outcomes is relatively 
low [22, 23]. Furthermore, a recent study has reported that 
obese living kidney donors (BMI ≥ 30) had a 30% increased 
risk of long-term mortality compared with their non-obese 
donors (BMI < 30) [24]. Accordingly, we need to select 
potential obese donors, and pay attention to not only short-
term outcome but also long-term outcome of living donor 
candidates.
Several limitations should be acknowledged in the pre-
sent study. The present study is a retrospective, single-
center analysis, and there may be a potential selection bias 
for living kidney donors. There were several rationales 
regarding the selection criteria for LDN or HARP although 
the final decision was made by the surgeon preference as 
described above. First female donors were prone to receive 
LDN because intraabdominal fat is generally less in female 
donors. Actually 69% of the LDN group were female com-
pared to 58% of the HARP group although not statistically 
significant. Second we have gained more experiences of 
LDN in obese donors over the years. Third surgical comfort 
would be better in LDN compared to HARP. Another con-
cern is long-term outcomes of obese donors. We examined 
the outcome at 1 year after donor nephrectomy; however, 
further long-term outcome after nephrectomy is not inves-
tigated in this study. The risk of lifestyle diseases and mor-
tality is higher in obese donors (BMI ≥ 30) as we described 
above, therefore careful long-term follow-up for obese 
donors is needed, and is provided in our center. In addition, 
this study does not include recipients’ outcome because we 
focus on only donor outcome based on the procedure (HARP 
vs. LDN) and donor BMI. However, a previous study has 
reported no significant differences in recipient acute rejec-
tion, allograft survival, and patient mortality across donor 
BMI categories [6]. Further prospective large studies are 
necessary to understand the long-term outcome of recipients 
from obese donors.
Conclusions
Our findings suggest that laparoscopic living donor nephrec-
tomy for donors with BMI ≥ 30 is safe and feasible with 
good postoperative outcomes. There were no significant 
differences regarding postoperative outcome between 
HARP and LDN. Furthermore, the outcome in donors with 
BMI ≥ 35 was comparable to donors with BMI 30–35. BMI 
itself should not be considered as a contraindication in 
selection criteria for living kidney donors, based on short-
term outcome. However, additional long-term follow-up of 
donors is needed to examine the impact of donor obesity on 
outcome including chronic kidney disease and kidney func-
tion after living donor nephrectomy.
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